235 related articles for article (PubMed ID: 26809275)
1. Circulating 25-Hydroxyvitamin D and Prostate Cancer Survival.
Mondul AM; Weinstein SJ; Moy KA; Männistö S; Albanes D
Cancer Epidemiol Biomarkers Prev; 2016 Apr; 25(4):665-9. PubMed ID: 26809275
[TBL] [Abstract][Full Text] [Related]
2. Serum vitamin D concentration and prostate cancer risk: a nested case-control study.
Ahn J; Peters U; Albanes D; Purdue MP; Abnet CC; Chatterjee N; Horst RL; Hollis BW; Huang WY; Shikany JM; Hayes RB;
J Natl Cancer Inst; 2008 Jun; 100(11):796-804. PubMed ID: 18505967
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer.
Li H; Stampfer MJ; Hollis JB; Mucci LA; Gaziano JM; Hunter D; Giovannucci EL; Ma J
PLoS Med; 2007 Mar; 4(3):e103. PubMed ID: 17388667
[TBL] [Abstract][Full Text] [Related]
4. Association of 25-Hydroxyvitamin D with Liver Cancer Incidence and Chronic Liver Disease Mortality in Finnish Male Smokers of the ATBC Study.
Lai GY; Wang JB; Weinstein SJ; Parisi D; Horst RL; McGlynn KA; Männistö S; Albanes D; Freedman ND
Cancer Epidemiol Biomarkers Prev; 2018 Sep; 27(9):1075-1082. PubMed ID: 29720370
[No Abstract] [Full Text] [Related]
5. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer.
Fang F; Kasperzyk JL; Shui I; Hendrickson W; Hollis BW; Fall K; Ma J; Gaziano JM; Stampfer MJ; Mucci LA; Giovannucci E
PLoS One; 2011 Apr; 6(4):e18625. PubMed ID: 21494639
[TBL] [Abstract][Full Text] [Related]
6. Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer.
Weinstein SJ; Mondul AM; Kopp W; Rager H; Virtamo J; Albanes D
Int J Cancer; 2013 Jun; 132(12):2940-7. PubMed ID: 23180681
[TBL] [Abstract][Full Text] [Related]
7. Circulating 25-hydroxyvitamin D up to 3 decades prior to diagnosis in relation to overall and organ-specific cancer survival.
Weinstein SJ; Mondul AM; Yu K; Layne TM; Abnet CC; Freedman ND; Stolzenberg-Solomon RZ; Lim U; Gail MH; Albanes D
Eur J Epidemiol; 2018 Nov; 33(11):1087-1099. PubMed ID: 30073448
[TBL] [Abstract][Full Text] [Related]
8. Circulating 25-Hydroxyvitamin D Concentration and Risk of Breast, Prostate, and Colorectal Cancers: The Melbourne Collaborative Cohort Study.
Heath AK; Hodge AM; Ebeling PR; Eyles DW; Kvaskoff D; Buchanan DD; Giles GG; Williamson EJ; English DR
Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):900-908. PubMed ID: 30842127
[TBL] [Abstract][Full Text] [Related]
9. Serum 25-hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men.
Layne TM; Weinstein SJ; Graubard BI; Ma X; Mayne ST; Albanes D
Cancer; 2017 Jul; 123(14):2698-2704. PubMed ID: 28369777
[TBL] [Abstract][Full Text] [Related]
10. Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study.
Albanes D; Mondul AM; Yu K; Parisi D; Horst RL; Virtamo J; Weinstein SJ
Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1850-60. PubMed ID: 21784952
[TBL] [Abstract][Full Text] [Related]
11. Association between serum 25-hydroxyvitamin D and serum sex steroid hormones among men in NHANES.
Anic GM; Albanes D; Rohrmann S; Kanarek N; Nelson WG; Bradwin G; Rifai N; McGlynn KA; Platz EA; Mondul AM
Clin Endocrinol (Oxf); 2016 Aug; 85(2):258-66. PubMed ID: 26991691
[TBL] [Abstract][Full Text] [Related]
12. Circulating 25-hydroxyvitamin D, vitamin D binding protein and risk of advanced and lethal prostate cancer.
Yuan C; Shui IM; Wilson KM; Stampfer MJ; Mucci LA; Giovannucci EL
Int J Cancer; 2019 May; 144(10):2401-2407. PubMed ID: 30411792
[TBL] [Abstract][Full Text] [Related]
13. Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis.
Holt SK; Kolb S; Fu R; Horst R; Feng Z; Stanford JL
Cancer Epidemiol; 2013 Oct; 37(5):666-70. PubMed ID: 23972671
[TBL] [Abstract][Full Text] [Related]
14. Long Term Association between Serum 25-Hydroxyvitamin D and Mortality in a Cohort of 4379 Men.
Meyer HE; Støer NC; Samuelsen SO; Blomhoff R; Robsahm TE; Brustad M; Giovannucci EL; Bjørge T
PLoS One; 2016; 11(3):e0151441. PubMed ID: 26986958
[TBL] [Abstract][Full Text] [Related]
15. Serum vitamin D, vitamin D binding protein, and lung cancer survival.
Anic GM; Weinstein SJ; Mondul AM; Männistö S; Albanes D
Lung Cancer; 2014 Dec; 86(3):297-303. PubMed ID: 25456734
[TBL] [Abstract][Full Text] [Related]
16. A Prospective Study of Serum Vitamin E and 28-Year Risk of Lung Cancer.
Huang J; Weinstein SJ; Yu K; Männistö S; Albanes D
J Natl Cancer Inst; 2020 Feb; 112(2):191-199. PubMed ID: 31077299
[TBL] [Abstract][Full Text] [Related]
17. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk.
Kirsh VA; Hayes RB; Mayne ST; Chatterjee N; Subar AF; Dixon LB; Albanes D; Andriole GL; Urban DA; Peters U;
J Natl Cancer Inst; 2006 Feb; 98(4):245-54. PubMed ID: 16478743
[TBL] [Abstract][Full Text] [Related]
18. Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Albanes D; Till C; Klein EA; Goodman PJ; Mondul AM; Weinstein SJ; Taylor PR; Parnes HL; Gaziano JM; Song X; Fleshner NE; Brown PH; Meyskens FL; Thompson IM
Cancer Prev Res (Phila); 2014 Sep; 7(9):886-95. PubMed ID: 24961880
[TBL] [Abstract][Full Text] [Related]
19. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial.
Kristal AR; Till C; Song X; Tangen CM; Goodman PJ; Neuhauser ML; Schenk JM; Thompson IM; Meyskens FL; Goodman GE; Minasian LM; Parnes HL; Klein EA
Cancer Epidemiol Biomarkers Prev; 2014 Aug; 23(8):1494-504. PubMed ID: 24732629
[TBL] [Abstract][Full Text] [Related]
20. Serum 25-hydroxyvitamin D, vitamin A, and lung cancer mortality in the US population: a potential nutrient-nutrient interaction.
Cheng TY; Neuhouser ML
Cancer Causes Control; 2012 Sep; 23(9):1557-65. PubMed ID: 22829430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
